news

ASN Kidney Week Meeting and American College of Toxicology’s Annual Meeting CUPERTINO, Calif., Oct. 25, 2018 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that two posters on DUR-928 will be presented at the ASN Kidney Week Meeting on Saturday, October 27 and one poster will be presented at the American College of Toxicology’s Annual Meeting, […]

CUPERTINO, Calif., Oct. 1, 2018 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today the appointment of Michael H. Arenberg to the position of Chief Financial Officer, effective October 15, 2018. Mr. Arenberg will be responsible for overseeing all financial and capital market activities at DURECT, including accounting, financial reporting, financial planning and analysis, and investor

CUPERTINO, Calif., Sept. 25, 2018 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown, President and CEO, will be presenting at the Cantor Fitzgerald Global Healthcare Conference on Wednesday, October 3 at 1:40 p.m. Eastern Time.  The conference is being held at the InterContinental New York Barclay hotel in New York City.  Institutional

– ORADUR®-Methylphenidate ER now called Methydur Sustained Release Capsules in Taiwan – Developed by Orient Pharma under a license to the ORADUR® technology from DURECT CUPERTINO, Calif., Sept. 18, 2018 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that Orient Pharma Co., Ltd., its licensee for certain Asian and South Pacific countries, has informed DURECT that

Milestone payment triggered by NDA approval of PERSERIS™ (risperidone) CUPERTINO, Calif., Aug. 30, 2018 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that it has received a $5 million milestone payment from Indivior PLC (LON: INDV), triggered by Indivior’s approval of the New Drug Application (NDA) for PERSERIS™ (risperidone) in July 2018.  On September 26,

CUPERTINO, Calif., Aug. 27, 2018 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown, President and CEO, will be presenting at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., on Thursday, September 6 at 9:10 a.m. Eastern Time.  The conference is being held at the St.

CUPERTINO, Calif., Aug. 6, 2018 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that its licensee, Pain Therapeutics (Nasdaq: PTIE) reported that it received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for Pain Therapeutics’ New Drug Application (NDA) for REMOXY® ER (oxycodone) extended-release capsules CII, which concluded that “The data

Live Webcast of Earnings Call Today at 4:30 p.m. Eastern Time CUPERTINO, Calif., Aug. 1, 2018 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended June 30, 2018 and provided a corporate update.   Total revenues were $3.4 million and net loss was $7.0 million for the three months

Approval triggers $5 million milestone payment to DURECT and future earn-out payments based on U.S. net sales CUPERTINO, Calif., July 30, 2018 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that Indivior PLC (LON: INDV) has reported that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for PERSERIS™ (risperidone), which

CUPERTINO, Calif., July 24, 2018 /PRNewswire/ — In conjunction with DURECT Corporation’s (Nasdaq: DRRX) second quarter 2018 financial results press release, you are invited to listen to a conference call that will be broadcast live over the internet on Wednesday, August 1, 2018 at 4:30 pm Eastern Time (1:30 pm Pacific Time). A live audio webcast